Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients.

ESMO Open · 2025 · PMC11758124 · PMID 39754976

Europe PMC DOI

hedged sentence

0.2750

closest p · 5.5× alpha

0.2750

boldest claim

The sentences

did not reach statistical significanceP = 0.275not close (p > 0.1)

Heterogeneity of treatment effect on DFS was observed according to HER2 status, with a statistically significant interaction in the ZL versus T comparison ( P = 0.007), while the interaction test did not reach statistical significance in the L versus T comparison ( P = 0.275).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.